Advertisement

Current Obstetrics and Gynecology Reports

, Volume 8, Issue 4, pp 136–138 | Cite as

Endometrial Cancer General Perspectives, Epidemiology

  • Görker SELEmail author
  • Müge Harma
  • Mehmet İbrahim Harma
Endometrial Cancer (G Sel, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Endometrial Cancer

Abstract

Purpose of Review

This paper focuses on the epidemiologic factors that are effective on the pathology of the endometrial malignancy. Based on previous reviews and recent articles on endometrial cancer, we sought to define risk factors and related diseases to endometrial malignancies.

Recent Findings

Previous studies have shown that phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. A major antagonist of PI3K activity is phosphatase and tensin homolog (PTEN), a tumor suppressor which is often mutated or lost in type I endometrial cancer cells.

Summary

Endometrial cancer is still a problem in developed countries since adiposity and sedentary way of life. However, we have not found a feasible way to screen endometrial malignancies. In the future, with the advancing of genetic studies, screening could be applicable.

Keywords

Endometrium Cancer Epidemiology Obesity Malignancy HNPCC 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Darbre PD, Williams G. Endocrine disruption and Cancer of reproductive tissues. InEndocrine disruption and human health: Academic Press; 2015. p. 177–200.CrossRefGoogle Scholar
  2. 2.
    Committee on Practice Bulletins-Gynecology, Society of Gynecologic Oncology. ACOG Practice Bulletin No. 149: Endometrial Cancer. Obstet Gynecol. 2015;125(4):1006–26.CrossRefGoogle Scholar
  3. 3.
    Zaino RJ, Kurman RJ, Diana KL, Paul Morrow C. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer. 1995;75(1):81–6.CrossRefGoogle Scholar
  4. 4.
    SEER Cancer Stat Facts: Uterine Cancer. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/corp.html.
  5. 5.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefGoogle Scholar
  6. 6.
    Tzur T, Kessous R, Weintraub AY. Current strategies in the diagnosis of endometrial cancer. Arch Gynecol Obstet. 2017;296(1):5–14.CrossRefGoogle Scholar
  7. 7.
  8. 8.
    Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134(2):385–92.CrossRefGoogle Scholar
  9. 9.
    Sorosky JI. Endometrial Cancer. Obstet Gynecol. 2008;111:436–47.CrossRefGoogle Scholar
  10. 10.
    Wise MR, Jordan V, Lagas A, Showell M, Wong N, Lensen S, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol. 2016;214(6):689–e1.CrossRefGoogle Scholar
  11. 11.
    Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30.CrossRefGoogle Scholar
  12. 12.
    Screening PD, Board PE. Endometrial Cancer prevention (PDQ®). InPDQ Cancer information summaries [Internet] 2018 Feb 1. National Cancer Institute (US).Google Scholar
  13. 13.
    Mendonça FM, de Sousa FR, Barbosa AL, Martins SC, Araújo RL, Soares R, et al. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64(2):182–9.CrossRefGoogle Scholar
  14. 14.
    Ayhan A, Reed N, Gültekin M, Dursun P. Textbook of Gynaecological oncology. Ankara. Endometrial cancer pg: Güneş Publishing; 2012. p. 372–9.Google Scholar
  15. 15.
    Görker S. (Diagnosis of abnormal uterine bleeding: office biopsy, dilatation curettage and hysteroscopy. Innovative approaches in health sciences) Anormal uterin kanamalarin tanisinda: ofis biyopsi, dilatasyon küretaj ve histeroskopinin yeri. Sağlık Bilimleri Alanında Yenilikçi Yaklaşımlar 1. Bası. Gece Publishing, Ankara, 2018: 279–285.Google Scholar
  16. 16.
    Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res. 2005;322(1):53–61.CrossRefGoogle Scholar
  17. 17.
    • Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–35 This is a recent article that describes PIK3CA mutations and its effect on growth factor-independent growth and survival. CrossRefGoogle Scholar
  18. 18.
    Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochimica et biophysica acta (bba)-proteins and proteomics. 2008;1784(1):150–8.CrossRefGoogle Scholar
  19. 19.
    Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. Apmis. 2009;117(10):693–707.CrossRefGoogle Scholar
  20. 20.
    •• Brinton LA, Trabert B. Role of estrogen and progesterone in obesity associated gynecologic cancers. In Focus on Gynecologic Malignancies 2018 (pp. 41–61). Springer, Cham. This is one of the most recent publications (chapter/book) describing role of estrogen and progesterone in obesity associated gynecologic cancers. This book also covers and describes relationships between other important metabolic factors with gynecological cancers. Google Scholar
  21. 21.
    Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer. 2014;24(3):384–93.CrossRefGoogle Scholar
  22. 22.
    Committee on Practice Bulletins-Gynecology, Society of Gynecologic Oncology. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014;124(5):1042–54.CrossRefGoogle Scholar
  23. 23.
    Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126(2):176–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Görker SEL
    • 1
    Email author
  • Müge Harma
    • 2
  • Mehmet İbrahim Harma
    • 2
  1. 1.Faculty of Medicine, Department of Obstetrics and GynecologyZonguldak Bülent Ecevit UniversityZonguldakTurkey
  2. 2.Faculty of Medicine, Department of Obstetrics and Gynecology-Gynecological OncologyZonguldak Bülent Ecevit UniversityZonguldakTurkey

Personalised recommendations